Treatment options in HR+/HER2- advanced breast cancer patients pretreated with nonsteroidal aromatase inhibitors: What does current evidence tell us?

Sabino De Placido, Paolo Pronzato

Research output: Contribution to journalArticlepeer-review

Abstract

Many postmenopausal women with advanced or metastatic breast cancer (BC) receive nonsteroidal aromatase inhibitors (NSAIs). Virtually all of them experience progression, but may still gain benefit from a different endocrine or targeted agent. We indirectly compare the results of trials on endocrine or targeted treatment in HR+/HER2- mBC patients who progressed after a prior NSAI therapy. Although with the limitations of any indirect comparison, evidence suggests that only the combination of everolimus and exemestane is associated with a prolonged progression-free survival and a more evident clinical benefit than its comparators. We speculate that prior NSAI therapy can 'per se' individuate patients eligible to everolimus. More robust data from head-to-head trials will provide more grounded evidence on this issue.

Original languageEnglish
Pages (from-to)975-981
Number of pages7
JournalFuture Oncology
Volume11
Issue number6
DOIs
Publication statusPublished - Mar 1 2015

Keywords

  • aromatase inhibitors
  • breast cancer
  • disease progression
  • endocrine treatment
  • second-line therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Medicine(all)

Fingerprint Dive into the research topics of 'Treatment options in HR<sup>+</sup>/HER2<sup>-</sup> advanced breast cancer patients pretreated with nonsteroidal aromatase inhibitors: What does current evidence tell us?'. Together they form a unique fingerprint.

Cite this